Mesdopetam
Dopamine D3 receptor antagonist
| Mesdopetam | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mesdopetam is a chemical compound that acts as a selective antagonist of the dopamine receptor D3. It is being investigated for its potential therapeutic effects in the treatment of Parkinson's disease and dyskinesia.
Pharmacology[edit]
Mesdopetam is known for its high affinity for the dopamine receptor D3, which is a subtype of the dopamine receptor family. The D3 receptor is primarily located in the limbic system of the brain, an area associated with emotion and cognition. By antagonizing this receptor, mesdopetam may help modulate the dopaminergic system, which is often dysregulated in conditions like Parkinson's disease.
Mechanism of Action[edit]
The primary mechanism of action of mesdopetam involves blocking the D3 receptors. This blockade can lead to a reduction in the overactivity of dopaminergic pathways that are implicated in the development of dyskinesia, a common side effect of long-term levodopa therapy in Parkinson's disease patients. By selectively targeting the D3 receptor, mesdopetam aims to provide therapeutic benefits without affecting other dopamine receptor subtypes, potentially reducing side effects.
Therapeutic Use[edit]
Mesdopetam is currently under investigation for its use in managing levodopa-induced dyskinesia in Parkinson's disease. Dyskinesia is a significant challenge in the management of Parkinson's disease, as it can severely impact the quality of life. Mesdopetam's selective action on the D3 receptor offers a novel approach to mitigating these symptoms.
Development and Research[edit]
Research on mesdopetam is ongoing, with clinical trials being conducted to evaluate its efficacy and safety profile. The compound is being developed by pharmaceutical companies with the aim of providing a new treatment option for patients suffering from Parkinson's disease-related dyskinesia.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
